<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126216</url>
  </required_header>
  <id_info>
    <org_study_id>Paccis-RCT_2005</org_study_id>
    <secondary_id>2005-003484-23</secondary_id>
    <secondary_id>107028</secondary_id>
    <nct_id>NCT01126216</nct_id>
  </id_info>
  <brief_title>Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer</brief_title>
  <acronym>Paccis-RCT</acronym>
  <official_title>Randomised Phase-III-trial of Simultaneous Radiochemotherapy (RCT) of Locally Advanced Head and Neck Cancer in the Stages III and IV A-B: Comparing Dose Reduced Radiotherapy (63,6 Gy) With Paclitaxel/Cisplatin to Standard Radiotherapy (70,2 Gy) With 5-Fluorouracil/Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reduced RT with Pac/Cis vs. standard RCT with 5-FU/Cis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard treatment for patients with advanced, unresectable head and neck cancer is a&#xD;
      platin-based simultaneous radiochemotherapy (RCT) (Pignon JP et al., Lancet&#xD;
      2000;355:949-955). However, irradiation dose is still debatable regarding local tumor control&#xD;
      and late toxicity. Moreover, it is still unclear which combination of different drugs might&#xD;
      be more effective.&#xD;
&#xD;
      In recent years, new drugs have been introduced in the field of head and neck cancer. The&#xD;
      Taxanes, namely Docetaxel and Paclitaxel, have been investigated in several phase&#xD;
      I/II-studies, and showed promising results concerning locoregional control rates and survival&#xD;
      data. The RTOG 97-03 trial (Garden et al., J Clin Oncol 2004; 22:2856-64) compared a RCT&#xD;
      either with Cisplatin/5-FU or Cisplatin/Paclitaxel. In this phase II-study an improvement of&#xD;
      local tumor control and disease free survival of 15-20% in favour of the Cisplatin/Paclitaxel&#xD;
      treatment arm was seen.&#xD;
&#xD;
      Therefore, our phase III-trial compares a standard RCT (70.6 Gy) with Cisplatin/5-FU to a RCT&#xD;
      with Cisplatin/Paclitaxel and reduced irradiation dose (63.6 Gy). Primary endpoint is to&#xD;
      proof superiority of the experimental Cisplatin/Paclitaxel treatment arm concerning&#xD;
      disease-free-survival. Secondary endpoints are locoregional tumor control, overall survival&#xD;
      and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    After an Interims analysis the Data Safety Monitoring board recommended this because no&#xD;
    significant difference between the two arms was seen and was not expected with an reasonable&#xD;
    recruitment of patients.&#xD;
&#xD;
    No interruptions of the trial were made.&#xD;
  </why_stopped>
  <start_date type="Actual">June 2010</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and Late Toxicity</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV/p16-Status</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Reduced RT + Pacitaxel/Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>63,6 Gy accelerated hyperfractionated radiotherapy with Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32, followed by a salvage operation or neck dissection if there is persisting tumor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard RT + 5-Fluorouracil/Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70,6 Gy accelerated hyperfractionated radiotherapy with 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33, followed by a salvage operation or neck dissection if there is persisting tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel/Cisplatin</intervention_name>
    <description>Experimental: Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32,</description>
    <arm_group_label>Reduced RT + Pacitaxel/Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Reduced RT</intervention_name>
    <description>Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy</description>
    <arm_group_label>Reduced RT + Pacitaxel/Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU/Cisplatin</intervention_name>
    <description>Active Comparator: 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33</description>
    <arm_group_label>Standard RT + 5-Fluorouracil/Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard RT</intervention_name>
    <description>Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy</description>
    <arm_group_label>Standard RT + 5-Fluorouracil/Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven, locally advanced stage III-IV A-B (UICC 2002) primary squamous&#xD;
             cell carcinoma of the oral cavity, the oropharynx, the hypopharynx, the supraglottic&#xD;
             larynx&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Written informed consent for the participation in the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate hepatic function: Bilirubin &gt; 2,0 mg/dl, SGOT, SGPT, AP, Gamma-GT &gt; 3 x ULN&#xD;
&#xD;
          -  Inadequate bone marrow function: leukocytes &lt; 3,5 x 10^9/l, platelets &lt; 100 x 10^9/l&#xD;
             or neutrophils &lt; 1,5 x 10^9/l&#xD;
&#xD;
          -  Serum creatinine &gt; 1,5 mg/dl, creatinine clearance &lt; 60ml/min&#xD;
&#xD;
          -  Uncontrolled severe somatic or psychological disease: e.g. unstable angina pectoris;&#xD;
             myocardial infarction during the last 6 months; significant cardial rhythm disorders;&#xD;
             apoplexy; high grade stenosis of the carotis; neurological or psychiatric disorders&#xD;
             including convulsive disorders; dementia; psychosis; active uncontrolled infection or&#xD;
             sepsis; liver cirrhosis; Child stage B,C; severe liver function disorders; marginal&#xD;
             changes in the blood count; severe kidney damage; HIV-infection&#xD;
&#xD;
          -  Acute infections&#xD;
&#xD;
          -  Fertile women without adequate contraception during and up to 6 months after therapy&#xD;
             (the method of contraception has to be high effective as described in the Note for&#xD;
             guidance on non-clinical safety studies for the conduct of human clinical trials for&#xD;
             pharmaceuticals (CPMP/ICH/286/95 mod) and it has to be discussed with the&#xD;
             investigator)&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Men, who are not willing to use adequate contraception during and up to 6 months after&#xD;
             therapy, that is discussed with the investigator&#xD;
&#xD;
          -  ECOG-Status &gt; 1&#xD;
&#xD;
          -  Reduced hearing function (especially higher frequencies)&#xD;
&#xD;
          -  Exsiccosis&#xD;
&#xD;
          -  Neuropathy, caused by cisplatin&#xD;
&#xD;
          -  Concurrent malignancies, with exception of adequately treated basal cell carcinoma of&#xD;
             the skin or in situ carcinoma or the cervix&#xD;
&#xD;
          -  Prior radiotherapy of the neck or chemotherapy&#xD;
&#xD;
          -  Distant metastasis&#xD;
&#xD;
          -  Recurrent carcinoma in the head and neck region&#xD;
&#xD;
          -  Prior neck-dissection or surgical intervention exceeding an exploratory excision&#xD;
&#xD;
          -  Known intolerance to 5-Fluorouracil&#xD;
&#xD;
          -  Known deficit of Dihydropyrimidine dehydrogenase (DPD)&#xD;
&#xD;
          -  Simultaneous therapy with Brivudin or other inhibitors of DPD&#xD;
&#xD;
          -  Known intolerance to Cisplatin or other substances that contain platin&#xD;
&#xD;
          -  Known intolerance to Paclitaxel or one of the included substances, especially to&#xD;
             Poly(oxyethylene)Rhizinusöl/Macrogolglycerol ricinoleate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Fietkau, MD</last_name>
    <role>Study Director</role>
    <affiliation>Strahlenklinik, Universitätsklinikum Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Coburg, Strahlentherapie, DiaCura</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik und Poliklinik für Strahlentherapie und Radiologische Onkologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Strahlenklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Klinik für Strahlentherapie und Radioonkologie</name>
      <address>
        <city>Frankfurt/M.</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum am Eichert, Praxis für Strahlentherapie und Klinik für Radioonkologie</name>
      <address>
        <city>Göppingen</city>
        <zip>73035</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes, Klinik für Strahlentherapie und Radioonkologie,</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik und Poliklinik für Hals-Nasen- und Ohrenkranke</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH Mönchengladbach, Klinik für Strahlentherapie</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum München Pasing und Perlach, Klinik für HNO</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus st. Josef Paderborn, Klinik für Strahlentherapie</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik und Poliklinik für Strahlentherapie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Elisabeth Straubing, Klinik für Hals-Nasen-Ohren-Heilkunde</name>
      <address>
        <city>Straubing</city>
        <zip>94315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ am Klinikum Mutterhaus der Borrmäerinnen, Strahlentherapie</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiochemotherapy</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>5-FU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

